Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a single-center pilot study to investigate the efficacy and safety of aerosolized
liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients
with bronchiolitis obliterans syndrome (BOS).
The primary objective is to evaluate the efficacy of liposomal cyclosporine A in the
treatment of chronic rejection. Pulmonary function and changes in BOS grade are the primary
end points.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, College Park